Blood pressure lowering effect of statin drugs with an application to rosuvastatin.
10.12793/tcp.2016.24.3.132
- Author:
Young A HEO
1
;
Mijeong SON
;
Kyungsoo PARK
Author Information
1. Department of Pharmacology, Yonsei University College of Medicine, Seoul 03722, Korea. kspark@yuhs.ac
- Publication Type:Original Article
- Keywords:
rosuvastatin;
systolic blood pressure;
diastolic blood pressure;
normotensive
- MeSH:
Blood Pressure*;
Cardiovascular Diseases;
Cross-Over Studies;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors*;
Hyperlipidemias;
Hypertension;
Male;
Metformin;
Receptors, Angiotensin;
Risk Factors;
Rosuvastatin Calcium*
- From:Translational and Clinical Pharmacology
2016;24(3):132-136
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hyperlipidemia and hypertension are among the major risk factors for cardiovascular disease (CVD) and they often co-exist within a single patient. Recently, many studies published results regarding the potential role of statins in decreasing blood pressure (BP) however there is still a controversy over the efficacy of statin therapy on BP. This study aimed to investigate the potential role of rosuvastatin in BP lowering properties in Korean population. Data were taken from three randomized, multiple-dose cross over studies for rosuvastatin, angiotensin II receptor blocker (ARB) and metformin monotherapies and the combined therapy of rosuvastatin and ARB, in total of 91 healthy male normotensive subjects. Measurements of systolic blood pressure (SBP), diastolic blood pressure (DBP) at the baseline before treatment begins and for 24 hours after the last dose were used in the analysis. The analysis variables used were (i) the mean change in steady-state BP from the baseline, symbolized as ΔBP, and (ii) the difference in ΔBP between the ARB monotherapy and the combined therapy, symbolized as ΔBP,d. The ΔBP and ΔBP,d for SBP from each study varied in -0.1 ~ -1.3 mmHg and 1.2 ~ 1.6 mmHg, respectively, and were not significantly different from zero. The ΔBP and ΔBP,d for DBP from each study varied in -2.8 ~ -1.4 mmHg and -2.9 ~ -1.8, respectively, which were statistically significant for ΔBP (p < 0.05) but was not for ΔBP,d (p > 0.05). These results indicated that the rosuvastatin monotherapy may produce small blood pressure lowing effect in DBP.
